|  Help  |  About  |  Contact Us

Search our database by keyword

Examples

  • Search this entire website. Enter identifiers, names or keywords for genes, diseases, strains, ontology terms, etc. (e.g. Pax6, Parkinson, ataxia)
  • Use OR to search for either of two terms (e.g. OR mus) or quotation marks to search for phrases (e.g. "dna binding").
  • Boolean search syntax is supported: e.g. Balb* for partial matches or mus AND NOT embryo to exclude a term

Search results 801 to 900 out of 1043 for Ace2

<< First    < Previous  |  Next >    Last >>
0.029s

Categories

Hits by Pathway

Hits by Category

Hits by Strain

Type Details Score
HT Experiment
GSE148360 | Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia (scRNA-seq: olfactory bulb)
 
Experiment Type: RNA-Seq
Study Type: Baseline
Source: GEO
•
•
•
•
•
HT Experiment
GSE151346 | Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia (scRNA-seq: olfactory mucosa)
 
Experiment Type: RNA-Seq
Study Type: Baseline
Source: GEO
•
•
•
•
•
Publication
37080957 | J:338826
First Author: Yang B
Year: 2023
Journal: Cell Discov
Title: A tissue specific-infection mouse model of SARS-CoV-2.
Volume: 9
Issue: 1
Pages: 43
•
•
•
•
•
Publication
29360543 | J:286359
 
First Author: Wang LA
Year: 2018
Journal: Neuropharmacology
Title: Coupling corticotropin-releasing-hormone and angiotensin converting enzyme 2 dampens stress responsiveness in male mice.
Volume: 133
Pages: 85-93
•
•
•
•
•
Publication
16330323 | J:129668
First Author: Fukui K
Year: 2005
Journal: Cell Metab
Title: The HNF-1 target collectrin controls insulin exocytosis by SNARE complex formation.
Volume: 2
Issue: 6
Pages: 373-84
•
•
•
•
•
Protein
Q9ESG4
Organism: Mus musculus/domesticus
Length: 222  
Fragment?: false
•
•
•
•
•
Protein
A2AHZ5
Organism: Mus musculus/domesticus
Length: 60  
Fragment?: true
•
•
•
•
•
Publication
32887790 | J:295328
 
First Author: Leist SR
Year: 2020
Journal: Dis Model Mech
Title: Cell and animal models of SARS-CoV-2 pathogenesis and immunity.
Volume: 13
Issue: 9
•
•
•
•
•
Strain
MGI:6695088 | STOCK Tg(CAG-ACE2)AC70Ctkt/Ctkt
Attribute String: transgenic, mutant stock
•
•
•
•
•
Publication
37441066 | J:338422
 
First Author: Calvier L
Year: 2023
Journal: Front Immunol
Title: Circulating Reelin promotes inflammation and modulates disease activity in acute and long COVID-19 cases.
Volume: 14
Pages: 1185748
•
•
•
•
•
Strain
MGI:6695092 | STOCK Tg(CAG-ACE2)AC22Ctkt/Ctkt
Attribute String: mutant stock, transgenic
•
•
•
•
•
Strain
MGI:6431338 | C57BL/6-Ace2<em1(ACE2)Yowa>
Attribute String: mutant strain, endonuclease-mediated mutation, coisogenic
•
•
•
•
•
Allele
Tg(Myh6-ACE2)2Rbre | MGI:6459903
Name: transgene insertion 2, Roger E Breitbart
Allele Type: Transgenic
Attribute String: Humanized sequence, Inserted expressed sequence
•
•
•
•
•
Strain
MGI:6470481 | FVB//N-Tg(Nphs1-ACE2)#Kdbu
Attribute String: coisogenic, mutant strain, transgenic
•
•
•
•
•
Allele
Ace2<tm1(ACE2)Dwnt> | MGI:6469881
Name: angiotensin converting enzyme 2; targeted mutation 1, David Wentworth
Allele Type: Targeted
Attribute String: Humanized sequence, Inserted expressed sequence
•
•
•
•
•
Strain
MGI:6469882 | B6.129S2(Cg)-Ace2<tm1(ACE2)Dwnt>/J
Attribute String: congenic, mutant strain, targeted mutation
•
•
•
•
•
Allele
Ace2<tm1.1(ACE2)Mdk> | MGI:6509009
Name: angiotensin converting enzyme 2; targeted mutation 1.1, Michael D Koob
Allele Type: Targeted
Attribute String: Humanized sequence, Inserted expressed sequence
•
•
•
•
•
Strain
MGI:6763026 | C57BL/6J-Ace2<em2Guru>/Mmjax
Attribute String: coisogenic, endonuclease-mediated mutation, mutant strain
•
•
•
•
•
Allele
Ace2<em1Guru> | MGI:6763023
Name: angiotensin converting enzyme 2; endonuclease-mediated mutation 1, Channabasavaiah Gurumurthy
Allele Type: Endonuclease-mediated
Attribute String: Humanized sequence
•
•
•
•
•
Allele
Ace2<em1(ACE2)Mlkn> | MGI:6842318
Name: angiotensin converting enzyme 2; endonuclease-mediated mutation 1, Mark L Kahn
Allele Type: Endonuclease-mediated
Attribute String: Conditional ready, Humanized sequence, Inserted expressed sequence, Null/knockout
•
•
•
•
•
Allele
Ace2<em2(ACE2/GFP)Mlkn> | MGI:6842319
Name: angiotensin converting enzyme 2; endonuclease-mediated mutation 2, Mark L Kahn
Allele Type: Endonuclease-mediated
Attribute String: Conditional ready, Humanized sequence, Inserted expressed sequence, Null/knockout, Reporter
•
•
•
•
•
Allele
Ace2<em2(ACE2)Mlkn> | MGI:7507528
Name: angiotensin converting enzyme 2; endonuclease-mediated mutation 2, Mark L Kahn
Allele Type: Endonuclease-mediated
Attribute String: Conditional ready, Humanized sequence, Inserted expressed sequence, Null/knockout
•
•
•
•
•
Allele
Gt(ROSA)26Sor<em1(CAG-N,CAG-ACE2)Liwe> | MGI:7570165
Name: gene trap ROSA 26, Philippe Soriano; endonuclease-mediated mutation 1, Wei Li
Allele Type: Endonuclease-mediated
Attribute String: Conditional ready, Epitope tag, Humanized sequence, Inserted expressed sequence
•
•
•
•
•
Strain
MGI:7657553 | C57BL/6N-Ace2<em7(ACE2)Cya>/Cya
Attribute String: coisogenic, endonuclease-mediated mutation, mutant strain
•
•
•
•
•
Genotype
Genotype
Symbol: Tg(Nphs1-ACE2)#Kdbu/?
Background: FVB//N-Tg(Nphs1-ACE2)#Kdbu
Zygosity: ot
Has Mutant Allele: true
•
•
•
•
•
Genotype
Genotype
Symbol: Tg(CAG-ACE2)AC70Ctkt/?
Background: either: (involves: BALB/c * C3H/HeJ * C57BL/6J) or (involves: C3H/HeJ * C57BL/6 * C57BL/6J)
Zygosity: ot
Has Mutant Allele: true
•
•
•
•
•
Genotype
Genotype
Symbol: Ace2/Ace2
Background: C57BL/6-Ace2
Zygosity: hm
Has Mutant Allele: true
•
•
•
•
•
Genotype
Genotype
Symbol: Tg(CAG-ACE2)AC63Ctkt/?
Background: either: (involves: BALB/c * C3H/HeJ * C57BL/6J) or (involves: C3H/HeJ * C57BL/6 * C57BL/6J)
Zygosity: ot
Has Mutant Allele: true
•
•
•
•
•
Genotype
Genotype
Symbol: Tg(Myh6-ACE2)1Rbre/?
Background: involves: FVB/N
Zygosity: ot
Has Mutant Allele: true
•
•
•
•
•
Genotype
Genotype
Symbol: Tg(Myh6-ACE2)2Rbre/?
Background: involves: FVB/N
Zygosity: ot
Has Mutant Allele: true
•
•
•
•
•
Publication
32333487 | J:287925
     
First Author: Natoli S
Year: 2020
Journal: Eur J Neurol
Title: Does SARS-Cov-2 invade the brain? Translational lessons from animal models.
•
•
•
•
•
Publication
38753462 | J:354789
First Author: Zhang Z
Year: 2024
Journal: Emerg Microbes Infect
Title: The lethal K18-hACE2 knock-in mouse model mimicking the severe pneumonia of COVID-19 is practicable for antiviral development.
Volume: 13
Issue: 1
Pages: 2353302
•
•
•
•
•
Publication
32498696 | J:288402
First Author: Lutz C
Year: 2020
Journal: Hum Genomics
Title: COVID-19 preclinical models: human angiotensin-converting enzyme 2 transgenic mice.
Volume: 14
Issue: 1
Pages: 20
•
•
•
•
•
Strain
MGI:6509010 | B6(Cg)-Ace2<tm1.1(ACE2)Mdk>/J
Attribute String: mutant strain, targeted mutation
•
•
•
•
•
Allele
Gt(ROSA)26Sor<em25(KRT18-ACE2)Mvw> | MGI:6877060
Name: gene trap ROSA 26, Philippe Soriano; endonuclease-mediated mutation 25, Michael V Wiles
Allele Type: Endonuclease-mediated
Attribute String: Epitope tag, Humanized sequence, Inserted expressed sequence
•
•
•
•
•
Strain
MGI:6865645 | NOD.Cg-Prkdc<scid> Il2rg<tm1Wjl> Ace2<em1Lutzy>/J
Attribute String: congenic, endonuclease-mediated mutation, targeted mutation, mutant strain, spontaneous mutation
•
•
•
•
•
Publication
19297479 | J:148946
First Author: Yoshikawa N
Year: 2009
Journal: J Virol
Title: Differential virological and immunological outcome of severe acute respiratory syndrome coronavirus infection in susceptible and resistant transgenic mice expressing human angiotensin-converting enzyme 2.
Volume: 83
Issue: 11
Pages: 5451-65
•
•
•
•
•
Strain
MGI:6763024 | C57BL/6J-Ace2<em1Guru>/Mmjax
Attribute String: coisogenic, endonuclease-mediated mutation, mutant strain
•
•
•
•
•
Strain
MGI:6877065 | C57BL/6J-Gt(ROSA)26Sor<em25(KRT18-ACE2)Mvw>/MvwJ
Attribute String: coisogenic, endonuclease-mediated mutation, mutant strain
•
•
•
•
•
Allele
Ace2<em1(ACE2)Synbl> | MGI:7261373
Name: angiotensin converting enzyme 2; endonuclease-mediated mutation 1, Synbal
Allele Type: Endonuclease-mediated
Attribute String: Humanized sequence, Inserted expressed sequence, Null/knockout
•
•
•
•
•
Allele
Ace2<em2.1(ACE2)Synbl> | MGI:7261383
Name: angiotensin converting enzyme 2; endonuclease-mediated mutation 2.1, Synbal
Allele Type: Endonuclease-mediated
Attribute String: Humanized sequence, Inserted expressed sequence, Null/knockout
•
•
•
•
•
Protein
Q8R0I0
Organism: Mus musculus/domesticus
Length: 805  
Fragment?: false
•
•
•
•
•
Protein
Q9D836
Organism: Mus musculus/domesticus
Length: 265  
Fragment?: true
•
•
•
•
•
Protein
F6X479
Organism: Mus musculus/domesticus
Length: 521  
Fragment?: true
•
•
•
•
•
Protein
Q3UXR1
Organism: Mus musculus/domesticus
Length: 557  
Fragment?: true
•
•
•
•
•
Protein
C7ECU2
Organism: Mus musculus/domesticus
Length: 787  
Fragment?: true
•
•
•
•
•
Protein
Q3URC9
Organism: Mus musculus/domesticus
Length: 805  
Fragment?: false
•
•
•
•
•
Protein Domain
IPR044366 | Spike_S1_RBD_SARS-CoV-2
Type: Domain
Description: The CoV Spike (S) protein is an envelope glycoprotein that plays the most important role in viral attachment, fusion, and entry into host cells, and serves as a major target for the development of neutralizing antibodies, inhibitors of viral entry, and vaccines. It is synthesised as a precursor protein that is cleaved into an N-terminal S1 subunit (~700 amino acids) and a C-terminal S2 subunit (~600 amino acids) that mediates attachment and membrane fusion, respectively. Three S1/S2 heterodimers assemble to form a trimer spike protruding from the viral envelope. The S1 subunit contains a receptor-binding domain (RBD), while the S2 subunit contains a hydrophobic fusion peptide and two heptad repeat regions. S1 contains two structurally independent domains, the N-terminal domain (NTD) and the C-terminal domain (C-domain). Depending on the virus, either the NTD or the C-domain can serve as the receptor-binding domain (RBD). Most CoVs, including SARS-CoV-2, SARS-CoV, and MERS-CoV use the C-domain to bind their receptors. However, CoV such as mouse hepatitis virus (MHV) uses the NTD to bind its receptor, mouse carcinoembryonic antigen related cell adhesion molecule 1a (mCEACAM1a). The S1 NTD contributes to the Spike trimer interface [, , , , ].This entry represents the RBD domain of Spike protein S1 subunit from SARS-CoV-2, which binds the extracellular peptidase domain of angiotensin-converting enzyme 2 (ACE2). It has been shown that the receptor binding induces the dissociation of the S1 with ACE2, prompting the S2 to transit from a metastable pre-fusion to a more-stable post-fusion state that is essential for membrane fusion [, , , ]. Recent structures revealed that only a single RBD is necessary for ACE2 binding and it is not yet clear if protrusion of the RBD from the S protein trimer is necessary for binding to ACE2 or the interconversion of the RBD between closed and open states represents an intrinsic property of the S protein []. During the pandemic, many amino acid substitutions have been reported in the S1 segment, being D614G the most commonly observed amino acid change from the reference sequence. Although it was estimated to be slightly destabilizing, it was hypothesized that it increases virus infectivity by increasing the total amount of S protein incorporated into virions. The most prevalent RBD substitution in the RBD is the T478I, located in a portion of a loop that contacts ACE2. However, most substitutions in the interface with ACE2 appear to be neutral or destabilizing, with none improving binding affinity [].SARS-CoV-2 RBD has a core formed by a twisted five-stranded antiparallel β-sheet (β1-7) with short helices and loops connecting them. Between the β4 and β7 strands in the core, there is an extended insertion, the receptor-binding motif (RBM), containing the short β5 and β6 strands, α4 and α5 helices and loops, which contains most of the contacting residues for binding to ACE2. There are nine cysteine residues in the RBD, eight of which form four pairs of disulfide bonds. Among these four pairs, three are in the core which help to stabilise the β-sheet structure, while the remaining pair connects the loops in the distal end of the RBM [].
•
•
•
•
•
Strain
MGI:6865656 | NOD.Cg-Prkdc<scid> Il2rg<tm1Wjl> Ace2<tm1(ACE2)Dwnt>/J
Attribute String: congenic, mutant strain, targeted mutation, spontaneous mutation
•
•
•
•
•
Strain
MGI:6865648 | B6.Cg-Tg(FCGRT)32Dcr Fcgrt<tm1Dcr> Ace2<em4Lutzy>/J
Attribute String: congenic, endonuclease-mediated mutation, mutant strain, transgenic, targeted mutation
•
•
•
•
•
Publication
17108019 | J:117824
First Author: Tseng CT
Year: 2007
Journal: J Virol
Title: Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor.
Volume: 81
Issue: 3
Pages: 1162-73
•
•
•
•
•
Strain
MGI:7261376 | C57BL/6J-Ace2<em1(ACE2)Synbl>/J
Attribute String: coisogenic, endonuclease-mediated mutation, mutant strain
•
•
•
•
•
Strain
MGI:7261384 | C(Cg)-Ace2<em2.1(ACE2)Synbl>/J
Attribute String: endonuclease-mediated mutation, mutant strain
•
•
•
•
•
Publication
18026570 | -
First Author: Fraga-Silva RA
Year: 2008
Journal: Mol Med
Title: The antithrombotic effect of angiotensin-(1-7) involves mas-mediated NO release from platelets.
Volume: 14
Issue: 1-2
Pages: 28-35
•
•
•
•
•
Publication
8513325 | -
First Author: Ward K
Year: 1993
Journal: Nat Genet
Title: A molecular variant of angiotensinogen associated with preeclampsia.
Volume: 4
Issue: 1
Pages: 59-61
•
•
•
•
•
Publication
10969042 | -
First Author: Donoghue M
Year: 2000
Journal: Circ Res
Title: A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9.
Volume: 87
Issue: 5
Pages: E1-9
•
•
•
•
•
Publication
2476171 | -
First Author: Ehlers MR
Year: 1989
Journal: Biochemistry
Title: Angiotensin-converting enzyme: new concepts concerning its biological role.
Volume: 28
Issue: 13
Pages: 5311-8
•
•
•
•
•
Publication
15010016 | -
First Author: Fuchs S
Year: 2004
Journal: Curr Hypertens Rep
Title: Newly recognized physiologic and pathophysiologic actions of the angiotensin-converting enzyme.
Volume: 6
Issue: 2
Pages: 124-8
•
•
•
•
•
Publication
1132082 | -
First Author: Goodfriend TL
Year: 1975
Journal: Circ Res
Title: Angiotensin III: (DES-Aspartic Acid-1)-Angiotensin II. Evidence and speculation for its role as an important agonist in the renin - angiotensin system.
Volume: 36
Issue: 6 Suppl 1
Pages: 38-48
•
•
•
•
•
Publication
23 | -
First Author: Flohr H
Year: 1975
Journal: Arzneimittelforschung
Title: Effect of etafenone on total and regional myocardial blood flow.
Volume: 25
Issue: 9
Pages: 1400-3
•
•
•
•
•
Publication
9 | -
First Author: Marniemi J
Year: 1975
Journal: Biochem Pharmacol
Title: Radiochemical assay of glutathione S-epoxide transferase and its enhancement by phenobarbital in rat liver in vivo.
Volume: 24
Issue: 17
Pages: 1569-72
•
•
•
•
•
Publication
467805 | -
First Author: Agardh CD
Year: 1979
Journal: Diabetes
Title: The effect of pronounced hypoglycemia on monoamine metabolism in rat brain.
Volume: 28
Issue: 9
Pages: 804-9
•
•
•
•
•
Publication
4675 | -
First Author: Lewis J
Year: 1976
Journal: J Stud Alcohol
Title: Washington report.
Volume: 37
Issue: 3
Pages: 409-14
•
•
•
•
•
Protein Domain
IPR000227 | Angiotensinogen
Type: Family
Description: Angiotensinogen is a component of the renin-angiotensin system (RAS), a hormone system that regulates blood pressure and fluid balance. It is also known as the renin substrate, and is a non-inhibitory member of the serpin family of proteinase inhibitors (MEROPS inhibitor family I4, clan ID, MEROPS identifier I04.953).Angiotensinogen is catalytically cleaved by renin to produce angiotensin I in response to lowered blood pressure. Angiotensin converting enzyme (ACE), subsequently removes a dipeptide to produce angiotensin II, the physiologically active peptide, which functions in the regulation of volume and mineral balance of body fluids [, ]. Angiotensin I and angiotensin II can be further processed to generate angiotensin III, which stimulates aldosterone release [], and angiotensin IV. Angiotensin 1-9 is cleaved from angiotensin-1 by ACE2 []and can be further processed by ACE to produce angiotensin 1-7, angiotensin 1-5 and angiotensin 1-4 [, ].Angiotensinogen is synthesised in the liver and secreted in plasma [, , , ]. Angiotensinogen appears to be associated with a predisposition to essential hypertension; it is also associated with pregnancy-induced hypertension (pih) (preeclampsia), a heterogeneous disorder that complicates 5-7% of all pregnancies and remains a leading cause of maternal, foetal and neonatal morbidity and mortality [].The entry represents the full precursor sequence of angiotensinogen.
•
•
•
•
•
Protein Domain
IPR033834 | Angiotensinogen_serpin_dom
Type: Domain
Description: Angiotensinogen is a component of the renin-angiotensin system (RAS), a hormone system that regulates blood pressure and fluid balance. It is also known as the renin substrate, and is a non-inhibitory member of the serpin family of proteinase inhibitors (MEROPS inhibitor family I4, clan ID, MEROPS identifier I04.953).Angiotensinogen is catalytically cleaved by renin to produce angiotensin I in response to lowered blood pressure. Angiotensin converting enzyme (ACE), subsequently removes a dipeptide to produce angiotensin II, the physiologically active peptide, which functions in the regulation of volume and mineral balance of body fluids [, ]. Angiotensin I and angiotensin II can be further processed to generate angiotensin III, which stimulates aldosterone release [], and angiotensin IV. Angiotensin 1-9 is cleaved from angiotensin-1 by ACE2 []and can be further processed by ACE to produce angiotensin 1-7, angiotensin 1-5 and angiotensin 1-4 [, ].Angiotensinogen is synthesised in the liver and secreted in plasma [, , , ]. Angiotensinogen appears to be associated with a predisposition to essential hypertension; it is also associated with pregnancy-induced hypertension (pih) (preeclampsia), a heterogeneous disorder that complicates 5-7% of all pregnancies and remains a leading cause of maternal, foetal and neonatal morbidity and mortality [].This entry represents the serpin domain of angiotensinogen.
•
•
•
•
•
Publication
18424768 | J:259115
First Author: Kowalczuk S
Year: 2008
Journal: FASEB J
Title: A protein complex in the brush-border membrane explains a Hartnup disorder allele.
Volume: 22
Issue: 8
Pages: 2880-7
•
•
•
•
•
Publication
26240152 | J:257334
First Author: Fairweather SJ
Year: 2015
Journal: J Biol Chem
Title: Molecular basis for the interaction of the mammalian amino acid transporters B0AT1 and B0AT3 with their ancillary protein collectrin.
Volume: 290
Issue: 40
Pages: 24308-25
•
•
•
•
•
Publication
17167413 | J:117490
First Author: Danilczyk U
Year: 2006
Journal: Nature
Title: Essential role for collectrin in renal amino acid transport.
Volume: 444
Issue: 7122
Pages: 1088-91
•
•
•
•
•
Publication
32643603 | J:291881
First Author: Sun J
Year: 2020
Journal: Cell
Title: Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment.
Volume: 182
Issue: 3
Pages: 734-743.e5
•
•
•
•
•
Publication
32553273 | J:290258
     
First Author: Hassan AO
Year: 2020
Journal: Cell
Title: A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies.
•
•
•
•
•
Publication
32937591 | J:351578
 
First Author: Brann DH
Year: 2020
Journal: Sci Adv
Title: Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia.
Volume: 6
Issue: 31
•
•
•
•
•
Publication
35879412 | J:331758
First Author: Biering SB
Year: 2022
Journal: Nat Genet
Title: Genome-wide bidirectional CRISPR screens identify mucins as host factors modulating SARS-CoV-2 infection.
Volume: 54
Issue: 8
Pages: 1078-1089
•
•
•
•
•
Publication
38486021 | J:361533
First Author: Fumagalli V
Year: 2024
Journal: Nat Immunol
Title: Antibody-independent protection against heterologous SARS-CoV-2 challenge conferred by prior infection or vaccination.
Volume: 25
Issue: 4
Pages: 633-643
•
•
•
•
•
Publication
33330862 | J:300213
     
First Author: Spalinger MR
Year: 2020
Journal: bioRxiv
Title: Identification of a Novel Susceptibility Marker for SARS-CoV-2 Infection in Human Subjects and Risk Mitigation with a Clinically Approved JAK Inhibitor in Human/Mouse Cells.
•
•
•
•
•
Publication
38077689 | J:357509
First Author: Benjakul S
Year: 2023
Journal: PNAS Nexus
Title: A pan-SARS-CoV-2-specific soluble angiotensin-converting enzyme 2-albumin fusion engineered for enhanced plasma half-life and needle-free mucosal delivery.
Volume: 2
Issue: 12
Pages: pgad403
•
•
•
•
•
Publication
37015225 | J:337324
First Author: Abdelfattah AS
Year: 2023
Journal: Neuron
Title: Sensitivity optimization of a rhodopsin-based fluorescent voltage indicator.
Volume: 111
Issue: 10
Pages: 1547-1563.e9
•
•
•
•
•
Publication
35523172 | J:325089
First Author: Chong Z
Year: 2022
Journal: Cell Rep
Title: Nasally delivered interferon-λ protects mice against infection by SARS-CoV-2 variants including Omicron.
Volume: 39
Issue: 6
Pages: 110799
•
•
•
•
•
Publication
36580912 | J:332438
First Author: Wu CT
Year: 2023
Journal: Cell
Title: SARS-CoV-2 replication in airway epithelia requires motile cilia and microvillar reprogramming.
Volume: 186
Issue: 1
Pages: 112-130.e20
•
•
•
•
•
Publication
33257679 | J:300960
First Author: Oladunni FS
Year: 2020
Journal: Nat Commun
Title: Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice.
Volume: 11
Issue: 1
Pages: 6122
•
•
•
•
•
Publication
35757773 | J:334874
 
First Author: Hedges JF
Year: 2022
Journal: Front Immunol
Title: An ADAM17-Neutralizing Antibody Reduces Inflammation and Mortality While Increasing Viral Burden in a COVID-19 Mouse Model.
Volume: 13
Pages: 918881
•
•
•
•
•
Publication
37491352 | J:338561
First Author: Robertson SJ
Year: 2023
Journal: Nat Commun
Title: Genetically diverse mouse models of SARS-CoV-2 infection reproduce clinical variation in type I interferon and cytokine responses in COVID-19.
Volume: 14
Issue: 1
Pages: 4481
•
•
•
•
•
Publication
- | J:321906
     
First Author: Bishop CR
Year: 2022
Journal: bioRxiv
Title: Mouse models of COVID-19 recapitulate inflammatory pathways rather than gene expression.
•
•
•
•
•
Publication
34273271 | J:335929
First Author: Bertoglio F
Year: 2021
Journal: Cell Rep
Title: A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations.
Volume: 36
Issue: 4
Pages: 109433
•
•
•
•
•
Publication
35090597 | J:335933
First Author: Konrath KM
Year: 2022
Journal: Cell Rep
Title: Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection.
Volume: 38
Issue: 5
Pages: 110318
•
•
•
•
•
Publication
33811809 | J:335894
First Author: Mills RJ
Year: 2021
Journal: Cell
Title: BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection.
Volume: 184
Issue: 8
Pages: 2167-2182.e22
•
•
•
•
•
Publication
32798445 | J:294058
First Author: Case JB
Year: 2020
Journal: Cell Host Microbe
Title: Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice.
Volume: 28
Issue: 3
Pages: 465-474.e4
•
•
•
•
•
Publication
35677392 | J:335951
First Author: Ding S
Year: 2022
Journal: iScience
Title: VE607 stabilizes SARS-CoV-2 Spike in the "RBD-up" conformation and inhibits viral entry.
Volume: 25
Issue: 7
Pages: 104528
•
•
•
•
•
Publication
35587469 | J:335948
First Author: Belouzard S
Year: 2022
Journal: PLoS Pathog
Title: Clofoctol inhibits SARS-CoV-2 replication and reduces lung pathology in mice.
Volume: 18
Issue: 5
Pages: e1010498
•
•
•
•
•
Publication
35986481 | J:335980
First Author: Appelberg S
Year: 2022
Journal: EMBO Mol Med
Title: A universal SARS-CoV DNA vaccine inducing highly cross-reactive neutralizing antibodies and T cells.
Volume: 14
Issue: 10
Pages: e15821
•
•
•
•
•
Publication
34237283 | J:335899
First Author: Jennewein MF
Year: 2021
Journal: Cell Rep
Title: Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects.
Volume: 36
Issue: 2
Pages: 109353
•
•
•
•
•
Publication
35602059 | J:354776
 
First Author: Tarrés-Freixas F
Year: 2022
Journal: Front Microbiol
Title: Heterogeneous Infectivity and Pathogenesis of SARS-CoV-2 Variants Beta, Delta and Omicron in Transgenic K18-hACE2 and Wildtype Mice.
Volume: 13
Pages: 840757
•
•
•
•
•
Publication
35134331 | J:335932
First Author: Stolp B
Year: 2022
Journal: Cell Rep
Title: SARS-CoV-2 variants of concern display enhanced intrinsic pathogenic properties and expanded organ tropism in mouse models.
Volume: 38
Issue: 7
Pages: 110387
•
•
•
•
•
Publication
34957381 | J:335920
First Author: Iwanaga N
Year: 2022
Journal: iScience
Title: ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV-2.
Volume: 25
Issue: 1
Pages: 103670
•
•
•
•
•
Publication
36494335 | J:335987
First Author: Biering SB
Year: 2022
Journal: Nat Commun
Title: SARS-CoV-2 Spike triggers barrier dysfunction and vascular leak via integrins and TGF-β signaling.
Volume: 13
Issue: 1
Pages: 7630
•
•
•
•
•
Publication
36508467 | J:333745
First Author: Parray HA
Year: 2022
Journal: PLoS Pathog
Title: A broadly neutralizing monoclonal antibody overcomes the mutational landscape of emerging SARS-CoV-2 variants of concern.
Volume: 18
Issue: 12
Pages: e1010994
•
•
•
•
•
Publication
34919799 | J:335935
First Author: Joyce MG
Year: 2021
Journal: Cell Rep
Title: SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.
Volume: 37
Issue: 12
Pages: 110143
•
•
•
•
•
Publication
33433624 | J:302314
 
First Author: Song E
Year: 2021
Journal: J Exp Med
Title: Neuroinvasion of SARS-CoV-2 in human and mouse brain.
Volume: 218
Issue: 3
•
•
•
•
•
Publication
36514310 | J:335990
First Author: Chen Y
Year: 2023
Journal: iScience
Title: Molecular basis for antiviral activity of two pediatric neutralizing antibodies targeting SARS-CoV-2 Spike RBD.
Volume: 26
Issue: 1
Pages: 105783
•
•
•
•
•
Publication
34338634 | J:336015
   
First Author: Ye G
Year: 2021
Journal: Elife
Title: The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates.
Volume: 10
•
•
•
•
•
Publication
35839775 | J:331767
First Author: Chen IP
Year: 2022
Journal: Cell Rep
Title: Viral E protein neutralizes BET protein-mediated post-entry antagonism of SARS-CoV-2.
Volume: 40
Issue: 3
Pages: 111088
•
•
•
•
•




MouseMine is a collaboration between MGI at The Jackson Laboratory and the InterMine project at the Cambridge Systems Biology Centre. MouseMine is funded through a grant from the NIH/NHGRI.The Jackson Laboratory makes no representation about the suitability or accuracy of this software or data for any purpose, and makes no warranties, either express or implied, including merchantability and fitness for a particular purpose or that the use of this software or data will not infringe any third party patents, copyrights, trademarks, or other rights. the software and data are provided "as is". This software and data are provided to enhance knowledge and encourage progress in the scientific community and are to be used only for research and educational purposes. Any reproduction or use for commercial purpose is prohibited without the prior express written permission of the Jackson Laboratory.

Copyright © 2017 by The Jackson Laboratory. All Rights Reserved

© 2002 - 2017 Department of Genetics, University of Cambridge, Downing Street,
Cambridge CB2 3EH, United Kingdom